Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TUXARIN ER vs CODEPREX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.
Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.
Major depressive disorder (FDA-approved as Auvelity),Treatment-resistant depression (off-label)
Cough suppression (FDA-approved)
1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.
Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
The terminal elimination half-life (t1/2) of chlorpheniramine is approximately 14–25 h in adults, allowing twice-daily dosing. Pseudoephedrine has a shorter t1/2 of 5–8 h in normal renal function, but the ER formulation maintains therapeutic levels for 12 h. In renal impairment, pseudoephedrine half-life prolongs significantly, requiring dose adjustment.
4-6 hours (prolonged to 10-12 hours in hepatic impairment)
Bupropion is extensively metabolized via CYP2B6 to hydroxybupropion, while dextromethorphan is metabolized primarily by CYP2D6 to dextrorphan. Both are further metabolized by other enzymes.
Codeine undergoes O-demethylation via CYP2D6 to morphine; also N-demethylation to norcodeine via CYP3A4; homatropine is minimally metabolized.
TUXARIN ER is a combination antihistamine/decongestant. The antihistamine component (e.g., chlorpheniramine) is extensively metabolized via CYP450; its metabolites and parent drug (∼68% over 48 h) appear in urine as unchanged drug and metabolites. The decongestant (e.g., pseudoephedrine) is primarily excreted unchanged in urine (∼70–90%) with the remainder metabolized in liver; renal elimination is p H-dependent, with acidic urine increasing excretion. Fecal elimination is negligible (<5%).
Renal: 60% as unchanged drug; Hepatic metabolism: 30% (inactive metabolites); Fecal: 10%
Chlorpheniramine: ∼70% bound to plasma proteins (mainly albumin). Pseudoephedrine: negligible protein binding (<20%).
92% (primarily to albumin)
Chlorpheniramine: Vd ≈ 3–5 L/kg, indicating extensive tissue distribution. Pseudoephedrine: Vd ≈ 2.5–3.5 L/kg, consistent with distribution into total body water. Larger Vd suggests sequestration in tissues like lungs and spleen.
1.5-2.0 L/kg (extensive tissue distribution)
Chlorpheniramine: Oral bioavailability ∼25–50% due to first-pass metabolism. Pseudoephedrine: Oral bioavailability ∼100% (>90% absorbed, low first-pass effect). The ER formulation maintains equivalent bioavailability with reduced peak concentrations.
Oral: 70-80% (first-pass metabolism reduces from 100% IV)
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild to moderate impairment; use with caution.
Hydrocodone: GFR 30-80 m L/min: no adjustment; GFR 10-29 m L/min: reduce dose by 50% or extend interval to every 8-12 hours; GFR <10 m L/min: use with caution, consider alternative. Acetaminophen: GFR <10 m L/min: extend dosing interval to every 8 hours.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment defined.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated due to acetaminophen toxicity risk and impaired hydrocodone metabolism.
Not recommended for children under 12 years. For children 12 years and older, same as adult dosing: 1 tablet every 12 hours.
Not recommended for pediatric use (no safety and efficacy data established).
Use with caution due to increased sensitivity to anticholinergic effects (e.g., confusion, urinary retention). Lower initial dose may be considered; avoid use in patients with prostate hypertrophy or glaucoma.
Start at low end of dosing range (1 tablet every 6 hours) due to increased sensitivity, reduced renal function, and risk of cognitive impairment.
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for clinical worsening and emergence of suicidal thoughts and behaviors.
Risk of respiratory depression, especially in children; contraindicated for postoperative pain management in children after tonsillectomy/adenoidectomy; contraindicated in children <12 years, and in children <18 years with risk factors for respiratory depression.
Increased risk of suicidal thoughts and behaviors; activation of mania/hypomania; seizures (dose-dependent); increased blood pressure; angle-closure glaucoma; serotonin syndrome; hepatotoxicity; neuropsychiatric reactions; allergic and anaphylactic reactions.
Respiratory depression; ultra-rapid metabolizers of CYP2D6 at risk of morphine toxicity; use in breastfeeding may cause infant opioid toxicity; anticholinergic effects of homatropine; risk of abuse and dependence; CNS depression with other depressants.
Concurrent use with MAOIs; seizure disorder; history of anorexia nervosa or bulimia; abrupt discontinuation of alcohol, benzodiazepines, or anticonvulsants; known hypersensitivity to any component; use of other bupropion-containing products; concomitant use with linezolid or methylene blue.
Hypersensitivity to codeine or homatropine; respiratory depression; acute or severe bronchial asthma; GI obstruction; paralytic ileus; children <12 years; children <18 years with tonsillectomy/adenoidectomy; use with MAOIs or within 14 days; breastfeeding women with CYP2D6 ultrarapid metabolism.
Avoid alcohol and grapefruit juice. Grapefruit juice may inhibit CYP3A4 metabolism of triprolidine, increasing its levels. High-tyramine foods (e.g., aged cheeses, cured meats) may interact with pseudoephedrine, increasing pressor effects. Take with or without food; food may reduce GI irritation but does not affect absorption.
Grapefruit juice may inhibit CYP2D6 and reduce codeine conversion to morphine, potentially decreasing efficacy. High-fat meals may delay absorption of codeine. Avoid alcohol.
TUXARIN ER contains chlorpheniramine and pseudoephedrine. Chlorpheniramine is an antihistamine classified as FDA Pregnancy Category B; animal studies show no risk but no adequate human studies. Pseudoephedrine is FDA Pregnancy Category C; in first trimester, case-control studies suggest a possible association with gastroschisis (odds ratio ~1.8-2.2). After 32 weeks, use may cause premature uterine contractions or fetal tachycardia. Avoid in third trimester due to risk of neonatal irritability and respiratory depression.
Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retrospective studies, though risk is low. Second and third trimesters: Risk of neonatal respiratory depression if used near term; chronic use may lead to neonatal withdrawal syndrome. Avoid if possible.
Chlorpheniramine is excreted into breast milk in small amounts (M/P ratio not established). Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3. Initial data indicate pseudoephedrine may reduce milk production by up to 24% with single doses. Use with caution; avoid in cases of established lactation insufficiency. American Academy of Pediatrics considers both drugs compatible with breastfeeding but may cause irritability in infants.
Codeine is excreted into breast milk. M/P ratio is approximately 2.5. Use with caution due to risk of infant CNS depression, especially in mothers who are CYP2D6 ultra-rapid metabolizers. AAP recommends lowest effective dose for shortest duration; monitor infant for drowsiness, difficulty breathing, or poor feeding.
No formal dose adjustments established for pregnancy. However, increased plasma volume and renal clearance in pregnancy may reduce pseudoephedrine levels; monitor clinical response. Avoid extended-release formulations if rapid BP fluctuations are a concern. Consider using the lowest effective dose for shortest duration.
No standard dose adjustment required, but avoid use in third trimester due to risk of neonatal respiratory depression. If used, use lowest effective dose for shortest duration. Monitor for signs of maternal respiratory depression; consider reduced dose in patients with decreased respiratory reserve.
TUXARIN ER is a fixed-dose combination of pseudoephedrine (120 mg) and triprolidine (2.5 mg) in an extended-release formulation. The delayed-release component may reduce dosing frequency to every 12 hours. Monitor for CNS stimulation; avoid in severe hypertension or coronary artery disease. Use caution in elderly due to anticholinergic effects (triprolidine).
CODEPREX (codeine/guaifenesin) is a combination antitussive/expectorant. Codeine is a prodrug metabolized by CYP2D6 to morphine; ultra-rapid metabolizers risk toxicity. Avoid in children <18 years due to respiratory depression risk. Use with caution in patients with COPD or respiratory insufficiency. Constipation is common; consider prophylactic laxatives.
Do not crush or chew the tablet; swallow whole with a full glass of water.,Take every 12 hours; do not exceed 2 tablets in 24 hours.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Notify your doctor if you have high blood pressure, heart disease, glaucoma, or urinary retention.,Do not use with other products containing antihistamines or decongestants.,Stop use and seek medical attention if you experience chest pain, rapid heartbeat, or severe dizziness.
Do not exceed recommended dose; may cause drowsiness, avoid driving or operating machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants as they increase sedation and respiratory depression risk.,Do not use in children under 18 years of age due to risk of serious breathing problems.,Contact your doctor if cough persists for more than 7 days or is accompanied by fever, rash, or persistent headache.,May cause constipation; increase fluid and fiber intake, and consider a stool softener if needed.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TUXARIN ER vs CODEPREX, answered by our medical review team.
TUXARIN ER is a Antitussive/decongestant combination that works by TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.. CODEPREX is a Antitussive Combination that works by Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TUXARIN ER and CODEPREX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TUXARIN ER is: 1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.. The standard adult dose of CODEPREX is: Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TUXARIN ER and CODEPREX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TUXARIN ER is classified as Category C. TUXARIN ER contains chlorpheniramine and pseudoephedrine. Chlorpheniramine is an antihistamine classified as FDA Pregnancy Category B; animal studies show no risk but no adequate h. CODEPREX is classified as Category C. Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.